Meeting your patients’ clinical needs is always your primary goal. The Amicus design delivers precision with the high efficiency you’ve come to expect.
One therapeutic procedure shouldn’t result in the need for another one. Amicus keeps median platelet loss at 10%,1 so you can perform MNC procedures on patients and donors with reduced need of associated platelet transfusion.3, 4
Source
1. FCRP-0297: Investigational Plan for the Harvesting of PBSC in G-CSF and Chemotherapy Mobilized Patients using Amicus Separator, December, 2000 and Post Hoc Analysis for FCRP-0297, March, 2014. Data on file.
2. Steininger PA, Strasser EF, Weiss D, Achenbach S, Zimmerman R, Ekstein R. First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors. Vox Sanguinis 2013; DOI 10.111/vox. 12102
3. Ikeda K, Ohto H, Kanno, T, Ogata T, Noji H, Ogawa K, Maruyama Y. Automated programs for collection of mononuclear cells and progenitor cells by two separators for peripheperipheral blood progenitor cell transplantation: comparison by a randomized crossover study. Transfusion. 2007 Jul;47:1234-1240.
4. Ikeda K, et al. Collection of MNCs and progenitor cells by two separators for PBPC transplantation: a randomized crossover trial. Transfusion. 2003 Jun;43:814-819
Contact your local Fresenius Kabi representative to learn more about Amicus Blue.
Refer to the Amicus Separator operator's manual for the full list of warnings and cautions associated with the use of the devices.
